Bitansky Guy, Avigdor Abraham, Vasilev Elena, Zlotnick Maya, Ribakovsky Elena, Benjamini Ohad, Nagler Arnon, Kedmi Meirav
Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Leuk Lymphoma. 2020 Nov;61(11):2645-2651. doi: 10.1080/10428194.2020.1786554. Epub 2020 Jul 9.
Progression of disease within 24 months of initial therapy (POD24) has previously been identified as a predictor of reduced overall survival (OS) for patients with follicular lymphoma (FL). Here we attempt to validate this finding in a retrospective cohort and understand whether the method by which progression is determined, clinically or radiographically, influences POD24 robustness. We reviewed records of 635 patients with FL and included 317 patients in our analysis. POD24 occurred in 21.5% of patients and it was evident that OS was significantly lower in the POD24 group. In multivariate analysis both POD24 and FLIPI were independently associated with inferior OS. POD24 that was detected by incidental routine imaging did not predict reduced OS as opposed to progression that was detected clinically. Although surveillance imaging is generally discouraged in FL, it still is a routine practice by many physicians, and therefore our findings are of significant clinical implications.
初始治疗24个月内疾病进展(POD24)先前已被确定为滤泡性淋巴瘤(FL)患者总生存期(OS)缩短的预测指标。在此,我们试图在一个回顾性队列中验证这一发现,并了解确定进展的方法(临床或影像学)是否会影响POD24的稳健性。我们回顾了635例FL患者的记录,并将317例患者纳入分析。21.5%的患者出现POD24,显然POD24组的OS显著更低。在多变量分析中,POD24和滤泡性淋巴瘤国际预后指数(FLIPI)均与较差的OS独立相关。与临床检测到的进展相反,偶然的常规成像检测到的POD24并不能预测OS降低。尽管一般不鼓励对FL进行监测成像,但许多医生仍将其作为常规做法,因此我们的发现具有重要的临床意义。